-
1
-
-
14944385553
-
Global cancer statistics, 2002
-
Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74-108 (Pubitemid 40372904)
-
(2005)
Ca-A Cancer Journal for Clinicians
, vol.55
, Issue.2
, pp. 74-108
-
-
Parkin, D.M.1
Bray, F.2
Ferlay, J.3
Pisani, P.4
-
2
-
-
70350204423
-
Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC)
-
Annual Proceedings, Orlando, FL, USA. May 29th-June 2nd; Abstract #LBA 4509
-
Van Cutsem E, Kang K, Chung H et al (2009) Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). American Society of Clinial Oncology, Annual Proceedings, Orlando, FL, USA. May 29th-June 2nd; Abstract #LBA 4509
-
(2009)
American Society of Clinial Oncology
-
-
Van Cutsem, E.1
Kang, K.2
Chung, H.3
-
3
-
-
70450209516
-
Pathological features of advanced gastric cancer (GC): Relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial
-
Orlando, FL, 29 May-2 June 2009; Abstract #4556
-
Bang Y, Chung H, Xu J et al (2009) Pathological features of advanced gastric cancer (GC): Relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. Amercan Society of Clinical Oncology, Annual Proceedings, Orlando, FL, 29 May-2 June 2009; Abstract #4556
-
(2009)
Amercan Society of Clinical Oncology, Annual Proceedings
-
-
Bang, Y.1
Chung, H.2
Xu, J.3
-
4
-
-
0036083396
-
The ubiquitin-proteasome proteolytic pathway: Destruction for the sake of construction
-
Glickman MH, Ciechanover A (2002) The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 82:373-428 (Pubitemid 34654457)
-
(2002)
Physiological Reviews
, vol.82
, Issue.2
, pp. 373-428
-
-
Glickman, M.H.1
Ciechanover, A.2
-
5
-
-
0037514596
-
Clinical update: Proteasome inhibitors in solid tumors
-
Lenz HJ (2003) Clinical update: proteasome inhibitors in solid tumors. Cancer Treat Rev 29(Suppl 1):41-48
-
(2003)
Cancer Treat Rev
, vol.29
, Issue.1 SUPPL.
, pp. 41-48
-
-
Lenz, H.J.1
-
6
-
-
0038189917
-
Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib
-
Cusack JC (2003) Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib. Cancer Treat Rev 29(Suppl 1):21-31
-
(2003)
Cancer Treat Rev
, vol.29
, Issue.1 SUPPL.
, pp. 21-31
-
-
Cusack, J.C.1
-
7
-
-
33745298519
-
Nuclear factor-κB in cancer development and progression
-
DOI 10.1038/nature04870, PII NATURE04870
-
Karin M (2006) Nuclear factor-kappaB in cancer development and progression. Nature 441:431-436 (Pubitemid 44050137)
-
(2006)
Nature
, vol.441
, Issue.7092
, pp. 431-436
-
-
Karin, M.1
-
8
-
-
2442630587
-
Nuclear Factor-κB p65 is a Prognostic Indicator in Gastric Carcinoma
-
Yamanaka N, Sasaki N, Tasaki A et al (2004) Nuclear factorkappaB p65 is a prognostic indicator in gastric carcinoma. Anticancer Res 24:1071-1075 (Pubitemid 38624940)
-
(2004)
Anticancer Research
, vol.24
, Issue.2 C
, pp. 1071-1075
-
-
Yamanaka, N.1
Sasaki, N.2
Tasaki, A.3
Nakashima, H.4
Kubo, M.5
Morisaki, T.6
Noshiro, H.7
Yao, T.8
Tsuneyoshi, M.9
Tanaka, M.10
Katano, M.11
-
9
-
-
0035542950
-
Nuclear factor-κB p65 (RelA) transcription factor is constitutively activated in human gastric carcinoma tissue
-
Sasaki N, Morisaki T, Hashizume K et al (2001) Nuclear factor-kappaB p65 (RelA) transcription factor is constitutively activated in human gastric carcinoma tissue. Clin Cancer Res 7:4136-4142 (Pubitemid 34044638)
-
(2001)
Clinical Cancer Research
, vol.7
, Issue.12
, pp. 4136-4142
-
-
Sasaki, N.1
Morisaki, T.2
Hashizume, K.3
Yao, T.4
Tsuneyoshi, M.5
Noshiro, H.6
Nakamura, K.7
Yamanaka, T.8
Uchiyama, A.9
Tanaka, M.10
Katano, M.11
-
10
-
-
14544303662
-
Proteasome inhibition as a novel therapeutic target in human cancer
-
DOI 10.1200/JCO.2005.11.030
-
Rajkumar SV, Richardson PG, Hideshima T, Anderson KC (2005) Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 23:630-639 (Pubitemid 46224241)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.3
, pp. 630-639
-
-
Rajkumar, S.V.1
Richardson, P.G.2
Hideshima, T.3
Anderson, K.C.4
-
11
-
-
34548357028
-
Antitumor effects and drug interactions of the proteasome inhibitor bortezomib (PS341) in gastric cancer cells
-
DOI 10.1097/CAD.0b013e32808bf9d8, PII 0000181320070700000007
-
Fujita T, Doihara H, Washio K et al (2007) Antitumor effects and drug interactions of the proteasome inhibitor bortezomib (PS341) in gastric cancer cells. Anticancer Drugs 18:677-686 (Pubitemid 47343660)
-
(2007)
Anti-Cancer Drugs
, vol.18
, Issue.6
, pp. 677-686
-
-
Fujita, T.1
Doihara, H.2
Washio, K.3
Ino, H.4
Murakami, M.5
Naito, M.6
Shimizu, N.7
-
12
-
-
43849086302
-
Effects of the proteasome inhibitor bortezomib alone, and in combination with chemotherapeutic agents in gastric cancer cell lines
-
Bae SH, Ryoo HM, Kim MK et al (2008) Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapeutic agents in gastric cancer cell lines. Oncol Rep 19:1027-1032 (Pubitemid 351802676)
-
(2008)
Oncology Reports
, vol.19
, Issue.4
, pp. 1027-1032
-
-
Bae, S.H.1
Ryoo, H.-M.2
Kim, M.K.3
Lee, K.H.4
Sin, J.-I.5
Hyun, M.S.6
-
14
-
-
0036023407
-
A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies
-
Aghajanian C, Soignet S, Dizon DS et al (2002) A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 8:2505-2511 (Pubitemid 34856332)
-
(2002)
Clinical Cancer Research
, vol.8
, Issue.8
, pp. 2505-2511
-
-
Aghajanian, C.1
Soignet, S.2
Dizon, D.S.3
Pien, C.S.4
Adams, J.5
Elliott, P.J.6
Sabbatini, P.7
Miller, V.8
Hensley, M.L.9
Pezzulli, S.10
Canales, C.11
Daud, A.12
Spriggs, D.R.13
-
15
-
-
0034594628
-
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
-
Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
-
(2000)
J Natl Cancer Inst
, vol.92
, pp. 205-216
-
-
Therasse, P.1
Arbuck, S.G.2
Eisenhauer, E.A.3
-
16
-
-
33845437420
-
WAF1, Ki-67 expression patterns in gastric cancer
-
DOI 10.1002/jcp.20833
-
Mattioli E, Vogiatzi P, Sun A et al (2007) Immunohistochemical analysis of pRb2/p130, VEGF, EZH2, p53, p16 (INK4A), p27(KIP1), p21(WAF1), Ki-67 expression patterns in gastric cancer. J Cell Physiol 210:183-191 (Pubitemid 44904714)
-
(2007)
Journal of Cellular Physiology
, vol.210
, Issue.1
, pp. 183-191
-
-
Mattioli, E.1
Vogiatzi, P.2
Sun, A.3
Abbadessa, G.4
Angeloni, G.5
D'Ugo, D.6
Trani, D.7
Gaughan, J.P.8
Vecchio, F.M.9
Cevenini, G.10
Persiani, R.11
Giordano, A.12
Claudio, P.P.13
-
17
-
-
2942720648
-
Expression profiling of colorectal carcinomas using tissue microarrays: Cell cycle regulatory proteins p21, p27, and p53 as immunohistochemical prognostic markers in univariate and multivariate analysis
-
Prall F, Ostwald C, Nizze H, Barten M (2004) Expression profiling of colorectal carcinomas using tissue microarrays: cell cycle regulatory proteins p21, p27, and p53 as immunohistochemical prognostic markers in univariate and multivariate analysis. Appl Immunohistochem Mol Morphol 12:111-121 (Pubitemid 38788759)
-
(2004)
Applied Immunohistochemistry and Molecular Morphology
, vol.12
, Issue.2
, pp. 111-121
-
-
Prall, F.1
Ostwald, C.2
Nizze, H.3
Barten, M.4
-
18
-
-
17644400134
-
Nuclear factor-κB activation correlates with better prognosis and Akt activation in human gastric cancer
-
DOI 10.1158/1078-0432.CCR-04-1282
-
Lee BL, Lee HS, Jung J et al (2005) Nuclear factor-kappaB activation correlates with better prognosis and Akt activation in human gastric cancer. Clin Cancer Res 11:2518-2525 (Pubitemid 40569448)
-
(2005)
Clinical Cancer Research
, vol.11
, Issue.7
, pp. 2518-2525
-
-
Byung, L.L.1
Hye, S.L.2
Jung, J.3
Sung, J.C.4
Chung, H.-Y.5
Woo, H.K.6
Jin, Y.-W.7
Chong, S.K.8
Seon, Y.N.9
-
19
-
-
21544441173
-
NF-κB activation and potentiation of proinflammatory responses by the Helicobacter pylori CagA protein
-
DOI 10.1073/pnas.0409873102
-
Brandt S, Kwok T, Hartig R et al (2005) NF-kappaB activation and potentiation of proinflammatory responses by the Helicobacter pylori CagA protein. Proc Natl Acad Sci U S A 102:9300-9305 (Pubitemid 40923558)
-
(2005)
Proceedings of the National Academy of Sciences of the United States of America
, vol.102
, Issue.26
, pp. 9300-9305
-
-
Brandt, S.1
Kwok, T.2
Hartig, R.3
Konig, W.4
Backert, S.5
-
20
-
-
20244384572
-
Helicobacter pylori-dependent NF-kappa B activation in newly established Mongolian gerbil gastric cancer cell lines
-
DOI 10.1111/j.1349-7006.2005.00030.x
-
Nozaki K, Tanaka H, Ikehara Y et al (2005) Helicobacter pyloridependent NF-kappa B activation in newly established Mongolian gerbil gastric cancer cell lines. Cancer Sci 96:170-175 (Pubitemid 40575918)
-
(2005)
Cancer Science
, vol.96
, Issue.3
, pp. 170-175
-
-
Nozaki, K.1
Tanaka, H.2
Ikehara, Y.3
Cao, X.4
Nakanishi, H.5
Azuma, T.6
Yamazaki, S.7
Yamaoka, Y.8
Shimizu, N.9
Mafune, K.-I.10
Kaminishi, M.11
Tatematsu, M.12
-
21
-
-
23044431754
-
A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer
-
DOI 10.1158/1078-0432.CCR-05-0081
-
Mackay H, Hedley D, Major P et al (2005) A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer. Clin Cancer Res 11:5526-5533 (Pubitemid 41060829)
-
(2005)
Clinical Cancer Research
, vol.11
, Issue.15
, pp. 5526-5533
-
-
Mackay, H.1
Hedley, D.2
Major, P.3
Townsley, C.4
Mackenzie, M.5
Vincent, M.6
Degendorfer, P.7
Tsao, M.-S.8
Nicklee, T.9
Birle, D.10
Wright, J.11
Siu, L.12
Moore, M.13
Oza, A.14
-
22
-
-
4644304196
-
Phase II trial of bortezomib for patients with advanced renal cell carcinoma
-
DOI 10.1200/JCO.2004.10.155
-
Kondagunta GV, Drucker B, Schwartz L et al (2004) Phase II trial of bortezomib for patients with advanced renal cell carcinoma. J Clin Oncol 22:3720-3725 (Pubitemid 41095212)
-
(2004)
Journal of Clinical Oncology
, vol.22
, Issue.18
, pp. 3720-3725
-
-
Kondagunta, G.V.1
Drucker, B.2
Schwartz, L.3
Bacik, J.4
Marion, S.5
Russo, P.6
Mazumdar, M.7
Motzer, R.J.8
-
23
-
-
77449083128
-
Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade ((R))) in chemotherapy-naive patients with advanced stage non-small cell lung cancer (NSCLC)
-
Li T, Ho L, Piperdi B et al (2009) Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade ((R))) in chemotherapy-naive patients with advanced stage non-small cell lung cancer (NSCLC). Lung Cancer 11:11
-
(2009)
Lung Cancer
, vol.11
, pp. 11
-
-
Li, T.1
Ho, L.2
Piperdi, B.3
-
24
-
-
34247855046
-
Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: A Southwest Oncology Group phase II trial (S0327)
-
PII 0124389420061100000013
-
Lara PN Jr, Chansky K, Davies AM et al (2006) Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327). J Thorac Oncol 1:996-1001 (Pubitemid 47181369)
-
(2006)
Journal of Thoracic Oncology
, vol.1
, Issue.9
, pp. 996-1001
-
-
Lara Jr., P.N.1
Chansky, K.2
Davies, A.M.3
Franklin, W.A.4
Gumerlock, P.H.5
Guaglianone, P.P.6
Atkins, J.N.7
Farneth, N.8
Mack, P.C.9
Crowley, J.J.10
Gandara, D.R.11
-
25
-
-
33646781960
-
Targeting the ubiquitinproteasome pathway in breast cancer therapy
-
Dees EC, Orlowski RZ (2006) Targeting the ubiquitinproteasome pathway in breast cancer therapy. Future Oncol 2:121-135
-
(2006)
Future Oncol
, vol.2
, pp. 121-135
-
-
Dees, E.C.1
Orlowski, R.Z.2
-
26
-
-
4644248931
-
Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors
-
DOI 10.1158/1078-0432.CCR-04-0422
-
Shah MH, Young D, Kindler HL et al (2004) Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors. Clin Cancer Res 10:6111-6118 (Pubitemid 39287516)
-
(2004)
Clinical Cancer Research
, vol.10
, Issue.18
, pp. 6111-6118
-
-
Shah, M.H.1
Young, D.2
Kindler, H.L.3
Webb, I.4
Kleiber, B.5
Wright, J.6
Grever, M.7
-
27
-
-
70349754173
-
A phase II evaluation of bortezomib in the treatment of recurrent platinumsensitive ovarian or primary peritoneal cancer: A Gynecologic Oncology Group study
-
Aghajanian C, Blessing JA, Darcy KM et al (2009) A phase II evaluation of bortezomib in the treatment of recurrent platinumsensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol 115:215-220
-
(2009)
Gynecol Oncol
, vol.115
, pp. 215-220
-
-
Aghajanian, C.1
Blessing, J.A.2
Darcy, K.M.3
-
28
-
-
17644400134
-
Nuclear factor-κB activation correlates with better prognosis and Akt activation in human gastric cancer
-
DOI 10.1158/1078-0432.CCR-04-1282
-
Lee BY, Lee HS, Jung J et al (2005) Nuclear factor-kB activation correlates with better prognosis and Akt activation in human gastric cancer. Clin Cancer Res 11:2518-2525 (Pubitemid 40569448)
-
(2005)
Clinical Cancer Research
, vol.11
, Issue.7
, pp. 2518-2525
-
-
Byung, L.L.1
Hye, S.L.2
Jung, J.3
Sung, J.C.4
Chung, H.-Y.5
Woo, H.K.6
Jin, Y.-W.7
Chong, S.K.8
Seon, Y.N.9
-
29
-
-
73449130242
-
Oncogenic pathway combinations predict clinical prognosis in gastric cancer
-
Ooi CH, Ivanova T, Wu J et al (2009) Oncogenic pathway combinations predict clinical prognosis in gastric cancer. PLoS Genetics 5:1-13
-
(2009)
PLoS Genetics
, vol.5
, pp. 1-13
-
-
Ooi, C.H.1
Ivanova, T.2
Wu, J.3
-
30
-
-
27644562277
-
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib
-
DOI 10.1016/j.ccr.2005.10.013, PII S153561080500334X
-
Chauhan D, Catley L, Li G et al (2005) A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 8:407-419 (Pubitemid 41579835)
-
(2005)
Cancer Cell
, vol.8
, Issue.5
, pp. 407-419
-
-
Chauhan, D.1
Catley, L.2
Li, G.3
Podar, K.4
Hideshima, T.5
Velankar, M.6
Mitsiades, C.7
Mitsiades, N.8
Yasui, H.9
Letai, A.10
Ovaa, H.11
Berkers, C.12
Nicholson, B.13
Chao, T.-H.14
Neuteboom, S.T.C.15
Richardson, P.16
Palladino, M.A.17
Anderson, K.C.18
-
31
-
-
33845288930
-
NPI-0052 enhances tumoricidal response to conventional cancer therapy in a colon cancer model
-
DOI 10.1158/1078-0432.CCR-06-1151
-
Cusack JC Jr, Liu R, Xia L et al (2006) NPI-0052 enhances tumoricidal response to conventional cancer therapy in a colon cancer model. Clin Cancer Res 12:6758-6764 (Pubitemid 44876845)
-
(2006)
Clinical Cancer Research
, vol.12
, Issue.22
, pp. 6758-6764
-
-
Cusack Jr., J.C.1
Liu, R.2
Xia, L.3
Chao, T.-H.4
Pien, C.5
Niu, W.6
Palombella, V.J.7
Neuteboom, S.T.C.8
Palladino, M.A.9
-
32
-
-
52649173202
-
Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFRindependent mitogenic kinase signaling pathways in pancreatic cancer cells
-
Sloss CM, Wang F, Liu R et al (2008) Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFRindependent mitogenic kinase signaling pathways in pancreatic cancer cells. Clin Cancer Res 14:5116-5123
-
(2008)
Clin Cancer Res
, vol.14
, pp. 5116-5123
-
-
Sloss, C.M.1
Wang, F.2
Liu, R.3
-
33
-
-
0141953292
-
Blockade of Hsp27 overcomes bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells
-
Chauhan D, Li G, Shringarpure R et al (2003) Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. Cancer Res 63:6174-6177 (Pubitemid 37255160)
-
(2003)
Cancer Research
, vol.63
, Issue.19
, pp. 6174-6177
-
-
Chauhan, D.1
Li, G.2
Shringarpure, R.3
Podar, K.4
Ohtake, Y.5
Hideshima, T.6
Anderson, K.C.7
-
34
-
-
0037443551
-
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: Therapeutic applications
-
DOI 10.1182/blood-2002-06-1768
-
Mitsiades N, Mitsiades CS, Richardson PG et al (2003) The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 101:2377-2380 (Pubitemid 36302084)
-
(2003)
Blood
, vol.101
, Issue.6
, pp. 2377-2380
-
-
Mitsiades, N.1
Mitsiades, C.S.2
Richardson, P.G.3
Poulaki, V.4
Tai, Y.-T.5
Chauhan, D.6
Fanourakis, G.7
Gu, X.8
Bailey, C.9
Joseph, M.10
Libermann, T.A.11
Schlossman, R.12
Munshi, N.C.13
Hideshima, T.14
Anderson, K.C.15
-
35
-
-
0036690648
-
PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis
-
Ling YH, Liebes L, Ng B et al (2002) PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis. Mol Cancer Ther 1:841-849
-
(2002)
Mol Cancer Ther
, vol.1
, pp. 841-849
-
-
Ling, Y.H.1
Liebes, L.2
Ng, B.3
-
36
-
-
0032510958
-
Superfolding of the partially unfolded core-glycosylated intermediate of human p-glycoprotein into the mature enzyme is promoted by substrate-induced transmembrane domain interactions
-
DOI 10.1074/jbc.273.24.14671
-
Loo TW, Clarke DM (1998) Superfolding of the partially unfolded core-glycosylated intermediate of human P-glycoprotein into the mature enzyme is promoted by substrate-induced transmembrane domain interactions. J Biol Chem 273:14671-14674 (Pubitemid 28272748)
-
(1998)
Journal of Biological Chemistry
, vol.273
, Issue.24
, pp. 14671-14674
-
-
Loo, T.W.1
Clarke, D.M.2
-
37
-
-
0035328584
-
Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: Implications for systemic nuclear factor-κB inhibition
-
Cusack JC Jr, Liu R, Houston M et al (2001) Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res 61:3535-3540 (Pubitemid 32694955)
-
(2001)
Cancer Research
, vol.61
, Issue.9
, pp. 3535-3540
-
-
Cusack Jr., J.C.1
Liu, R.2
Houston, M.3
Abendroth, K.4
Elliott, P.J.5
Adams, J.6
Baldwin Jr., A.S.7
-
38
-
-
67349263502
-
Recent results of phase II study of PS-341 (bortezomib) with or without irinotecan in patients (pts) with advanced gastric adenocarcinomas (AGA)
-
Orlando, FL, USA, 15-17 January 2007
-
Ocean AJ, Schnoll-Sussman F, Chen XE et al (2007) Recent results of phase II study of PS-341 (bortezomib) with or without irinotecan in patients (pts) with advanced gastric adenocarcinomas (AGA). Gastrointestinal Cancer Symposium, Orlando, FL, USA, 15-17 January 2007
-
(2007)
Gastrointestinal Cancer Symposium
-
-
Ocean, A.J.1
Schnoll-Sussman, F.2
Chen, X.E.3
-
39
-
-
43049090496
-
Bortezomib, paclitaxel, and carboplatin as a first-line regimen for patients with metastatic esopahgeal, gastric, and gastroesophageal cancer
-
Jatoi A, Dakhil SR, Foster NR et al (2008) Bortezomib, paclitaxel, and carboplatin as a first-line regimen for patients with metastatic esopahgeal, gastric, and gastroesophageal cancer. J Thorac Oncol 3:516-520
-
(2008)
J Thorac Oncol
, vol.3
, pp. 516-520
-
-
Jatoi, A.1
Dakhil, S.R.2
Foster, N.R.3
|